Skip to main content
Fig. 1 | Alzheimer's Research & Therapy

Fig. 1

From: Generation of a new transgenic mouse model for assessment of tau gene silencing therapies

Fig. 1

Expression of tau in bigenic tTA/TUL-Y74 mice. The diagram above the figure depicts the expected mRNA for the transgene and its products (not precisely to scale). The cDNA for the transgene construct was designed to encode 156 bp of 5′ untranslated sequence and 1227 bp of 3′ untranslated sequence from the human tau gene, providing additional targeting options for knockdown. The levels of tau in the forebrains of two tTA/TUL mice (aged 2 months) are compared to that of Tg4510 P301L tau mice (aged 3 months) and iP301L tau mice (aged 24 months), which express human tau from the same cDNA used in the TUL mice. The blots were probed with a mouse monoclonal antibody that specifically reacts with human tau (clone Tau-13). The tau protein created by processing of the TUL poly-protein would be expected to possess a C-terminal ubiquitin moiety and thus migrate to a slightly higher molecular weight

Back to article page